Institut de recherche biomédicale
    Vous êtes ici : Accueil / L'Institut / Séminaires / Présentation de la Biotech EG427

    Présentation de la Biotech EG427

    Webinaire de l'Institut Cochin

    Jeudi 18 mars 2021 - 12h00 - En visioconférence. Pour obtenir le lien d'accès à la visioconférence, envoyez un mail à


    Pierre Denys,  
    Fondateur - Médecin de Médecine Physique et de Réadaptation et chef du pôle de Neuro-urologie de l’hôpital de Garches

    Alberto Epstein,  
    Fondateur et CSO, directeur de recherche émérite au CNRS

    François Giuliano,  
    Fondateur - Urologue Chirurgien des Hôpitaux à l’APHP et responsable de l’activité de recherche expérimentale « Physiopathologie et Biothérapie Dysfonctions Uro-Génito-Sexuelles d’origine Neurologique » à l’UVSQ-Paris Saclay

    Philippe Chambon,  
    Fondateur et CEO


    invités par Pierre-Olivier Couraud



    EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. By exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1), notably its ability to establish lifelong latency in peripheral neurons, EG 427 ensures highly specific and durable expression of the transgene to treat, in the long run, patients with severe, chronic and localized diseases, starting with peripheral nervous system disorders. HSV-1 presents a number of advantages with respect to other viral vectors. Alberto Epstein will review and highlight all aspects of the attractiveness of defectives HSV1 vectors for gene therapy.

    The most advanced product of the company is developed for the treatment of the neurogenic bladder also called neurogenic detrusor overactivity (NDO). Spinal cord injuries (SCI) lead to a variety of dysfunctions including neurogenic bladder due to the impairment of the neural command of motor and visceral functions. NDO is the first cause of re-hospitalization for SCI patients and significantly impacts patient’s quality of life. Pierre Denys, a world-wide expert in the field will summarize the main aspect of the physiopathology of the disease in light of the unique therapeutic solution offers by EG427.

    Moreover, the company is currently evaluating the potential of its pinpoint gene therapy in other indications targeting conditions involving the peripheral nervous system. François Giuliano will resume the main indications of interest under investigation by EG427.


    Finally, Philippe Chambon will share with the audience his 30 years of experience in healthcare venture capital in the US and will highlight the key factors require to be successful in the inception of a new company. The genesis of EG427 will illustrate the early phase of development of any successful venture.